Acknowledgments Figures were created with BioRender.com
Currently, there are four main treatments propelling this market forward: Ozempic and Wegovy (semaglutide: a GLP-1 agonist, developed by Novo Nordisk) Mounjaro and Zepbound (tirzepatide: a dual agonist targeting both GLP-1 and GIP (Gastric inhibitory polypeptide) receptors, developed by Eli Lilly) These medications are administered subcutaneously with the assistance of injection pens
Whether you are managing type 2 diabetes or beginning a medically supported weight management plan, MedsRus provides a clinically safe route to treatment
Following the 52-week extension phase, a follow-up period of 5 weeks is planned to allow complete wash-out of semaglutide before the final trial visit at week 161
For instance, Novo Nordisks CagriSema, a combination of semaglutide and cagrilintide, has shown superior results in lowering blood glucose and promoting weight loss compared to semaglutide alone
The result rates may vary from person to person and due to the lifestyle/food intake you have